Back to Cell Types

SUIT-2Homo sapiens (Human)Cancer cell line

Also known as: SUIzo Tumor-2, Suit2, SUIT2, SUIT 2, Suit-2

🤖 AI SummaryBased on 10 publications

Quick Overview

Human pancreatic cancer cell line with known genetic alterations.

Detailed Summary

SUIT-2 is a human pancreatic cancer cell line derived from a pancreatic ductal adenocarcinoma. It is characterized by specific genetic alterations, including mutations in the K-ras, p53, and p16 genes, as well as alterations in the DPC4/Smad4 gene. These genetic changes are common in pancreatic cancer and contribute to tumor progression. SUIT-2 has been used in studies to investigate the molecular mechanisms of pancreatic cancer and to test potential therapeutic strategies. The cell line is part of the Cancer Cell Line Encyclopedia (CCLE) and has been analyzed for its genomic and transcriptomic profiles, providing valuable insights into the genetic landscape of pancreatic cancer.

Research Applications

Genetic and molecular profilingDrug sensitivity and resistance studiesInvestigation of tumor progression mechanisms

Key Characteristics

Mutations in K-ras, p53, and p16Alterations in DPC4/Smad4Part of the Cancer Cell Line Encyclopedia (CCLE)

Generated on 6/20/2025

Basic Information

Database ID	CVCL_3172
Species	Homo sapiens (Human)
Tissue Source	Liver[UBERON:UBERON_0002107]

Donor Information

Age	73
Age Category	Adult
Sex	Male
Race	asian

Disease Information

Disease	Pancreatic ductal adenocarcinoma
Lineage	Pancreas
Subtype	Pancreatic Adenocarcinoma
OncoTree Code	PAAD

DepMap Information

Source Type	HSRRB
Source ID	ACH-000652_source

Known Sequence Variations

Type	Gene/Protein	Description	Zygosity	Note	Source
MutationSimple	TP53	p.Arg273His (c.818G>A)	Homozygous	-	Unknown, PubMed=16264262
MutationSimple	KRAS	p.Gly12Asp (c.35G>A)	Unspecified	-	PubMed=29786757
MutationSimple	CDKN2A	p.His83Tyr (c.247C>T) (p.Ala97Val, c.290C>T)	Unspecified	-	PubMed=11787853

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin

X

CSF1PO

11,12

D13S317

9,11

D16S539

9

D18S51

16

D21S11

29,30

D3S1358

16

D5S818

11,12

D7S820

9,11

D8S1179

14,15

FGA

20,23

Penta D

11

Penta E

10

TH01

6

TPOX

8,10

vWA

16,17

Gene Expression Profile

Gene expression levels and statistical distribution

Loading cohorts...

Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

Pan-cancer proteomic map of 949 human cell lines.";

Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.

Cancer Cell 40:835-849.e8(2022).

Quantitative proteomics of the Cancer Cell Line Encyclopedia.";

Sellers W.R., Gygi S.P.

Cell 180:387-402.e16(2020).

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Sellers W.R.

Nature 569:503-508(2019).

Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.

Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.

Nature 568:511-516(2019).

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

Cancer Res. 79:1263-1273(2019).

Differential effector engagement by oncogenic KRAS.";

McCormick F.

Cell Rep. 22:1889-1902(2018).

A landscape of pharmacogenomic interactions in cancer.";

Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

Cell 166:740-754(2016).

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Loewer M., Sahin U., Castle J.C.

Genome Med. 7:118.1-118.7(2015).

Metabolite profiling stratifies pancreatic ductal adenocarcinomas into subtypes with distinct sensitivities to metabolic inhibitors.

Manning G., Settleman J., Hatzivassiliou G., Evangelista M.

Proc. Natl. Acad. Sci. U.S.A. 112:E4410-E4417(2015).

A resource for cell line authentication, annotation and quality control.

Neve R.M.

Nature 520:307-311(2015).

A comprehensive transcriptional portrait of human cancer cell lines.

Settleman J., Seshagiri S., Zhang Z.-M.

Nat. Biotechnol. 33:306-312(2015).

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

Nature 483:603-607(2012).

Alterations of the p53 tumor-suppressor gene and ki-ras oncogene in human pancreatic cancer-derived cell-lines with different metastatic potential.

Shimazoe T., Nawata H., Kono A.

Oncol. Rep. 1:1223-1227(1994).

A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

Haber D.A.

Cancer Res. 70:2158-2164(2010).

Genome-wide analysis of pancreatic cancer using microarray-based techniques.

Harada T., Chelala C., Crnogorac-Jurcevic T., Lemoine N.R.

Pancreatology 9:13-24(2009).

A recurrent chromosome translocation breakpoint in breast and pancreatic cancer cell lines targets the neuregulin/NRG1 gene.

Edwards P.A.W., Chaffanet M.

Genes Chromosomes Cancer 37:333-345(2003).

Taxotere resistance in SUIT. Taxotere resistance in pancreatic carcinoma cell line SUIT 2 and its sublines.

Liu B., Staren E., Iwamura T., Appert H., Howard J.

World J. Gastroenterol. 7:855-859(2001).

Genetic profile of 22 pancreatic carcinoma cell lines. Analysis of K-ras, p53, p16 and DPC4/Smad4.

Lohr J.-M., Scarpa A.

Virchows Arch. 439:798-802(2001).

Non-random chromosomal rearrangements in pancreatic cancer cell lines identified by spectral karyotyping.

Sheer D., Moore P.S., Scarpa A., Edwards P.A.W., Lemoine N.R.

Int. J. Cancer 91:350-358(2001).

Establishment and characterization of a human pancreatic cancer cell line (SUIT-2) producing carcinoembryonic antigen and carbohydrate antigen 19-9.

Iwamura T., Katsuki T., Ide K.

Jpn. J. Cancer Res. 78:54-62(1987).

Correlation between CA19-9 production in vitro and histological grades of differentiation in vivo in clones isolated from a human pancreatic cancer cell line (SUIT-2).

Hidaka K., Setoguchi T., Katsuki T.

J. Gastroenterol. Hepatol. 7:512-519(1992).

Web Resources

cellosaurus.org